HOOKIPA Pharma (HOOK) said Thursday it struck a deal to sell its key assets from its HB-400 program for hepatitis B virus and HB-500 program for human immunodeficiency virus program to Gilead Sciences (GILD) for up to $10 million.
These programs are currently in clinical development, the company said in a regulatory filing. Gilead will not acquire other assets, including its HB-500 phase 1b clinical trial.
HOOKIPA said it will receive $3 million upfront at closing, with up to $7 million due in three phases.
Shares of HOOKIPA rose past 11% in recent trading.
Price: 1.72, Change: +0.20, Percent Change: +13.16
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。